ABSTRACT
Mucins are large highly glycosylated molecules that have been postulated to interfere with certain cell-cell interactions. Steric, charge and specific signalling effects have been postulated for the inhibition by cell-surface mucin molecules. In this report we evaluate the inhibitory effects of bovine submaxillary mucin (BSM), a mucin without specific lymphocyte interactions, on lymphocyte function. BSM inhibits the adhesion of lymphocytes when coimmobilized with intercellular adhesion molecule-1 (ICAM-1) and blocks the activation of T lymphocytes when coimmobilized with anti-CD3. These data demonstrate a general mucin effect on lymphocyte adhesion and activation that is primarily steric in nature and implicates mucins as general barriers to lymphocyte-tumour cell interactions. Mucin blockade of cell-cell interactions may explain why mucinous tumours are often associated with a poor prognosis.
Subject(s)
Lymphocytes/drug effects , Mucins/pharmacology , Animals , Antigen-Presenting Cells/physiology , CD3 Complex/immunology , Cell Adhesion/drug effects , Female , Intercellular Adhesion Molecule-1/physiology , Ligands , Lymphocyte Activation , Lymphocyte Function-Associated Antigen-1/physiology , Lymphocytes/immunology , Lymphocytes/physiology , Mice , Mice, Inbred BALB C , Tumor Cells, CulturedABSTRACT
L6 is an IgG2a murine monoclonal antibody which we have demonstrated binds well to HT29 human colon carcinoma cells by flow cytometry, whole cell ELISA, and mixed hemadsorption. In vitro cytotoxicity studies revealed that the monoclonal antibody L6-cytosine deaminase (L6-CD) immunoconjugate plus the nontoxic prodrug, 5-fluorocytosine (5-FC), is equivalent to 5-fluorouracil (5-FU) in its ability to kill HT29 cells. Human alpha-interferon (A/D) was able to enhance this cytotoxic effect. The I.C.50's revealed that very small amounts of L6-CD are needed for this cytotoxic effect (approximately, 5 pg/ml resulted in 50% viability). The limiting factor was the amount of 5-FC employed with L6-CD (3 microM yielded 50% cell viability). alpha-Interferon (A/D) lowered the requirement of 5-FC to 1 microM to achieve 50% cell lethality. In vivo biodistribution experiments indicated that 1 microgram of L6-CD is nonspecifically taken up by the liver and spleen and cleared rapidly from the blood. Significant localization of L6-CD to HT29 tumors occurred only when 99 micrograms of unlabeled L6-CD was added to 1 microgram of 125I-labeled immunoconjugate injected intravenously. Further augmentation of tumor/blood ratios without reduction in percent injected dose per gram of tumor was possible with the intravenous injection of 100 micrograms of anti-idiotypic monoclonal antibody 13B, 24 hours after L6-CD, which bound unreacted L6-CD and cleared it from the blood. The addition of 100,000 U of alpha-interferon (A/D) given intraperitoneally every day increased the clearance of L6-CD by the liver and spleen, but impaired tumor localization (percent injected dose per gram). These studies demonstrated that in vivo localization of the L6-CD conjugate to HT29 tumors could be optimized by injecting excess L6-CD followed by an equal amount of L6 anti-idiotype mAb 13B, 24 hours after L6-CD.
Subject(s)
Adenosine Deaminase/pharmacokinetics , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal/toxicity , Colonic Neoplasms/drug therapy , Immunotoxins/pharmacokinetics , Immunotoxins/toxicity , Interferon Type I/pharmacology , Animals , Antibodies, Anti-Idiotypic/blood , Cell Survival/drug effects , Flucytosine/pharmacokinetics , Flucytosine/toxicity , Hemadsorption , Humans , Liver/metabolism , Mice , Mice, Nude , Recombinant Proteins , Spleen/metabolism , Tissue Distribution , Tumor Cells, CulturedABSTRACT
BACKGROUND: Paclitaxel is an antimitotic agent isolated from the Pacific yew tree. It has demonstrated antitumor activity in several cancers and is the first of a new class of antineoplastic agents containing a taxane ring system. Its levels in serum and urine have been measured previously by high performance liquid chromatography (HPLC). In this study, the authors developed two competitive radioimmunoassay methods to determine whether they could reliably be used to measure levels of paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. METHODS: A monoclonal antibody prepared against paclitaxel was employed in an immunoradiometric assay (IRMA), in which 125I-labeled antibody was used, and in a more conventional tritiated radioimmunoassay (RIA),in which 3H-paclitaxel was used. RESULTS: Both radioimmunoassays detected levels of paclitaxel in sera that were comparable to those observed with HPLC. However, the IRMA was the most sensitive. Only the IRMA was able to detect low levels of paclitaxel in cerebrospinal fluid after paclitaxel infusion and in sera 3 weeks after infusion. Both the IRMA and RIA methods were able to detect paclitaxel in ascitic and pleural fluids. CONCLUSIONS: Monitoring paclitaxel levels reliably in sera and other bodily fluids is possible with these radioimmunoassays and may be of value in predicting and preventing toxicity and optimizing paclitaxel treatments.
Subject(s)
Paclitaxel/analysis , Radioimmunoassay/methods , Antibodies, Monoclonal , Humans , Metabolic Clearance Rate , Paclitaxel/blood , Paclitaxel/cerebrospinal fluid , Pleural Effusion/chemistryABSTRACT
T, Tn, and sialyated Tn (sTn) are pancarcinoma antigens, and increased expression of these carbohydrate epitopes has been correlated with a poor prognosis in several epithelial malignancies. Ten murine monoclonal antibodies have been generated to these antigens, and compared by ELISA and immunohistochemistry to established mAbs reactive with these antigens. Nine mAbs (3 IgM and 6 IgG) reactive with synthetic T-human serum albumin (T-HSA) were produced after immunizing BALB/c mice with a synthetic T-keyhole limpet hemocyanin glycoconjugate (T-KLH). An additional IgM mAb (145.22) was produced in mice immunized with erythrocytes isolated from a patient with Tn syndrome. Three IgM and six IgG1 mAbs reactive with T-HSA did not react with natural T antigen present on desialyated glycophorin. All three IgM and several IgG1 mAbs, however, did react with LS-174T, a mucinous colon carcinoma cell line, 647V, a human bladder carcinoma cell line, and TA3Ha, a murine mammary carcinoma cell line as well as fresh frozen colon carcinomas. MAb 145.22 reacted with both natural and synthetic sources of sTn and Tn, as well as with LS-174T cells and mucin deposits in 10/11 colon carcinomas on fresh-frozen sections. MAb B72.3 reacted strongly with ovine submaxillary mucin (OSM) and sTn-HSA, while mAb CC49, a second-generation mAb to TAG-72 carcinoma mucin, reacted strongly with OSM, less strongly with desialyated OSM, and only weakly with sTn-HSA, suggesting that the epitope specificity for mAb CC49 is distinct from that of B72.3.
Subject(s)
Antibodies, Monoclonal/immunology , Antibody Specificity/immunology , Antigens, Neoplasm/immunology , Antigens, Tumor-Associated, Carbohydrate/immunology , Sialoglycoproteins/immunology , Animals , Antibodies, Monoclonal/biosynthesis , Antibodies, Neoplasm/biosynthesis , Antigens, Viral, Tumor/immunology , Enzyme-Linked Immunosorbent Assay , Humans , Immunohistochemistry , MiceABSTRACT
Twenty seven B cell neoplasms were examined by high performance thin layer chromatography (HPTLC) and immune thin layer chromatography (ITLC) to determine ganglioside expression. Patterns of expression in the cells were compared with conventional morphology, genotype, and glycoprotein immunophenotype. Patterns of ganglioside expression were found for each of the tumor types analyzed (5 acute lymphoblastic lymphomas (ALL), 5 Burkitt's Lymphomas (BL), 4 chronic lymphocytic leukemias (CLL), and 3 diffuse poorly differentiated lymphomas (DPDL), 7 diffuse histiocytic lymphomas (DHL), and 3 multiple myelomas (MM). GM3 was the predominant ganglioside found in all B cell neoplasms except multiple myeloma where GM2 was equivalent to GM3. GM1 was detected by ITLC in all B cell tumors, but significant amounts were found by HPTLC only in ALL, CLL, and DHL. Small amounts of GD3 and GD2 were found in several B cell neoplasms. Significant amounts of other gangliosides were not found. The expression of GM2 on the MM cell lines, a cell type derived from outside of the nervous system, is unusual. This high level of expression was also seen in metabolic labeling studies. GM2 was readily detectable in the SKMM1 human multiple myeloma cell line by flow cytometry and served as a target for human complement-mediated cytotoxicity. Although the functions of gangliosides are largely known, the patterns of gangliosides found for this system of human B cell malignancies may serve to provide targets for specific immunotherapy and clues to their functions.
Subject(s)
Burkitt Lymphoma/metabolism , Gangliosides/analysis , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Lymphoma, B-Cell/metabolism , Multiple Myeloma/metabolism , Burkitt Lymphoma/pathology , Chromatography, Thin Layer , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma, B-Cell/pathology , Lymphoma, Large B-Cell, Diffuse/metabolism , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Non-Hodgkin/metabolism , Lymphoma, Non-Hodgkin/pathology , Multiple Myeloma/pathology , Phenotype , Tumor Cells, CulturedABSTRACT
A type I ribosome inactivating protein, gelonin, was linked to Lym-1, a murine monoclonal antibody reactive with a polymorphic determinant of class II HLA-DR histocompatibility leukocyte antigen (HLA) on human lymphoma cells, via a disulfide linkage using the heterobifunctional cross-linking agent, N-succinimidyl-3-(2-pyridyldithio) propionate. This immunotoxin was purified from unreacted gelonin and unconjugated Lym-1 by fast protein liquid chromatography using sephacryl S-300 gel filtration and blue sepharose affinity gradient separation. Binding of Lym-1-gelonin immunoconjugate to human Raji Burkitt's lymphoma cells was demonstrated by indirect immunofluorescence using flow cytometry. Lym-1-gelonin was very active in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium salt and sulforhodamine B in vitro cytotoxicity assays against the Raji lymphoma cell line and confirmed the fact that monoclonal antibody Lym-1 internalizes into human lymphoma cells. A weaker cytostatic antiproliferative effect was also noted for unconjugated Lym-1. gamma-interferon augmented the antiproliferative effects of Lym-1-gelonin conjugate and unconjugated Lym-1, by having a direct cytotoxic effect on the Raji cells. Tumor necrosis factor-alpha also enhanced the antiproliferative effect of unconjugated Lym-1, but did not significantly augment the cytotoxic activity of the Lym-1-gelonin conjugate. These results suggest that anti-HLA class II monoclonal antibodies may be useful in constructing immunotoxins for the treatment of human lymphomas and leukemias expressing HLA class II antigens, and that unconjugated anti-HLA class II monoclonal antibodies may be therapeutically useful in conjunction with recombinant cytokines, especially gamma-interferon.
Subject(s)
Antibodies, Monoclonal/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Burkitt Lymphoma/drug therapy , Growth Inhibitors/pharmacology , Immunoconjugates/pharmacology , Interferon-gamma/pharmacology , Plant Proteins/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Animals , Antibodies, Monoclonal/metabolism , Antineoplastic Agents, Phytogenic/metabolism , Binding Sites, Antibody , Burkitt Lymphoma/metabolism , Burkitt Lymphoma/pathology , Cells , Drug Synergism , Growth Inhibitors/toxicity , Humans , Immunoconjugates/isolation & purification , Immunoconjugates/metabolism , Mice , Plant Proteins/metabolism , Ribosome Inactivating Proteins, Type 1 , Tumor Cells, CulturedABSTRACT
Using immunohistochemical techniques and whole-cell enzyme-linked immunosorbent assay, we have determined that monoclonal antibodies (mAbs) B72.3 and CC49, which are widely used in the diagnosis and treatment of several human epithelial cancers, are expressed in a transplantable rat colon carcinoma cell line, K12-TRb. MAbs B72.3 and CC49 react with tumor-associated glycoprotein-72 (TAG-72) which is a carcinoma mucin molecule expressed in colon, breast, pancreatic, ovarian, lung, and gastric cancers. The carbohydrate epitope for mAb B72.3 is sialylated Tn (sTn), whereas CC49 reacts with an unknown carbohydrate epitope. K12-TRb is a transplantable rat colon carcinoma cell line derived from a dimethylhydrazine tumor which grows as progressive tumors in syngeneic BD IX rats. We found that the carbohydrate epitopes for mAbs B72.3 and CC49, including sTn, were more tumor-restricted in the rat than in humans. The only binding these had mAbs to normal rat tissue was to small-intestinal mucosa. MAbs B72.3 and CC49 were radiolabeled with iodine-125 (125I) and injected intravenously into BD IX rats containing subcutaneously grown syngeneic K12-TRb tumors. Biodistribution experiments were conducted by dissecting groups of three rats on days 2, 4, 7, and 14 after injection of radiolabeled mAbs. These experiments confirmed that maBs B72.3 and CC49 localize to K12-TRb tumors in vivo, and that the higher affinity mAb CC49 localized better than mAb B72.3. Gamma-camera imaging of subcutaneous K12-TRb tumors was successfully performed using 125I-labeled mAb CC49. The importance of this model is that mAbs B72.3 and CC49, immunoconjugates of these mAbs, and vaccines containing their corresponding carbohydrate epitopes, including sTn, can be studied in a relevant immunocompetent syngeneic rat colon carcinoma model.
Subject(s)
Antibodies, Monoclonal/analysis , Antigens, Tumor-Associated, Carbohydrate/immunology , Antigens, Tumor-Associated, Carbohydrate/physiology , Carcinoma/chemistry , Colonic Neoplasms/chemistry , Mucins/immunology , Sialoglycoproteins/immunology , Animals , Antibodies, Monoclonal/pharmacokinetics , Carcinoma/immunology , Colonic Neoplasms/immunology , Enzyme-Linked Immunosorbent Assay/methods , Epitopes/chemistry , Female , Humans , Immunohistochemistry , Mice , Mucins/chemistry , Neoplasms, Experimental/immunology , Radionuclide Imaging , Rats , Rats, Inbred Strains , Transplantation, IsogeneicABSTRACT
To study the immune effects of complement-fixing cytotoxic monoclonal antibodies (mAbs) in a syngeneic immunocompetent animal model, mouse mAbs reactive with the transplantable rat colon carcinoma K12/TRb were generated. This system was used in part because rats have a complement system superior to that of mice. Seven murine IgG mAbs that reacted strongly with cell surface determinants of the K12/TRb rat colon carcinoma cell line were produced by immunizing MRL/Mp-1pr/1pr autoimmune mice, known to produce an increased amount of complement-fixing IgG2a and IgG3 immune cytotoxic antibodies, with K12/TRb cells. These mAbs were screened for their specificity of reaction, and two of these mAbs were extensively tested for their ability to lyse cells in vitro and localize to K12/TRb tumors in syngeneic BD IX rats. IgG2a mAbs 27-3 and 61-5 were able to mediate both complement and lymphocyte cytotoxicity in vitro and localize to subcutaneous tumors and liver metastases in this immunocompetent rat model.
Subject(s)
Antibodies, Monoclonal/immunology , Colonic Neoplasms/immunology , Cytotoxicity, Immunologic , Immunocompetence , Liver Neoplasms, Experimental/immunology , Skin Neoplasms/immunology , Animals , Antibodies, Monoclonal/metabolism , Antigens, Neoplasm/analysis , Complement System Proteins/immunology , Female , Liver Neoplasms, Experimental/secondary , Mice , RatsABSTRACT
Partially desialylated ovine submaxillary mucin plus an immunological adjuvant has been used by us to induce a humoral immune response to Tn antigen and sialylated Tn in colon cancer patients at risk of recurrence. Peripheral blood lymphocytes were purified from one of these patients with a high IgM titer reactive with Tn antigen transformed with Epstein-Barr virus and subsequently fused with a human-mouse heteromyeloma cell line, HMMA2.11TG/O. Clones were screened and subcloned using an enzyme-linked immunoassay and four stable IgM-secreting clones were tested for reactivity with a variety of natural and synthetic antigens, paraffin-embedded colon carcinomas and normal colonic mucosa to determine their specificity. Four human IgM monoclonal antibodies reactive predominantly with Tn antigen were produced and shown to react with a mucinous human colon carcinoma cell line, LS-174T, and with paraffin-embedded human colon carcinomas. We conclude that modified ovine submaxillary mucin is an effective vaccine for generating a humoral immune response directed to Tn antigen present on human colon cancer.
Subject(s)
Antibodies, Monoclonal/biosynthesis , Antibodies, Neoplasm/biosynthesis , Antigens, Tumor-Associated, Carbohydrate/immunology , Mucins/immunology , Animals , Antibody Specificity , Colonic Neoplasms/immunology , Epitopes/immunology , Humans , Hybridomas/immunology , Immunoglobulin M/biosynthesis , Immunohistochemistry , Mice , Mucins/chemistry , Sheep , Sialic Acids/chemistry , Sialic Acids/immunology , Submandibular Gland/immunology , Tumor Cells, Cultured/immunology , VaccinationABSTRACT
Fifty-three patients with AIDS-related Kaposi's sarcoma and no previous treatment with cytotoxic chemotherapy enrolled in a phase II multicenter study to evaluate the safety and efficacy of weekly doxorubicin treatment. Doxorubicin was given intravenously at a dose of 15 mg/m2. Patients were stratified for purposes of analyses by tumor burden and coexistence of HIV-associated signs and symptoms; stratum I included patients with cutaneous disease alone and no symptoms, and stratum II included patients with visceral disease, tumor-associated edema, a previous opportunistic infection, or systemic symptoms. Fifty-one patients were evaluable for toxicity and 50 for tumor response. Five patients had a partial response (10%); 32, a minor response (64%); 12, no change (24%); and one, progression (2%) as the best measurable response. Partial response durations ranged from 4 to 14 weeks. Fifteen patients subsequently showed progression while on treatment. A significantly greater number of patients in stratum I (20.1%) had a partial response compared with those in stratum II (0%, p = 0.009). The major toxicities included nausea (37%), stomatitis (9.8%), mucositis (13.7%), and moderate to severe neutropenia (71%). Neutropenia was dose limiting and resulted in discontinuation of doxorubicin in 18% of the patients. Two patients developed cardiac toxicity. In conclusion, doxorubicin treatment induced relatively few tumor responses and remission durations were short. Treatment was limited by a high rate of toxicity.
Subject(s)
Acquired Immunodeficiency Syndrome/complications , Doxorubicin/administration & dosage , Sarcoma, Kaposi/drug therapy , AIDS-Related Opportunistic Infections/complications , Adult , Doxorubicin/adverse effects , Drug Administration Schedule , Humans , Male , Middle Aged , Neutropenia/chemically induced , Sarcoma, Kaposi/blood , Sarcoma, Kaposi/etiologyABSTRACT
Tn and sialylated Tn (sTn) are blood group-related epitopes expressed on mucins of colon carcinoma and other epithelial tumors and are, therefore, potential targets for immunological control. We have immunized 20 colorectal cancer patients at high risk for recurrence with a vaccine consisting of partially desialylated ovine submaxillary gland mucin (modified OSM) which contains both Tn and sTn determinants. Six patients were treated with modified OSM alone (group 1), eight patients were treated with modified OSM and the immunological adjuvant DETOX (group 2), and six patients were treated with modified OSM and Bacillus Calmette-Guérin (group 3). Pre- and postvaccination sera were tested by enzyme-linked immunosorbent assay and dot blot immune stains for antibodies reactive with modified OSM. Antibody titers increased in 4 of 8 patients immunized with modified OSM and DETOX, in 5 of 6 patients immunized with modified OSM and B. Calmette-Guérin, and in 0 of 6 patients receiving modified OSM without adjuvant. The specificity of induced IgM and IgG antibodies was confirmed by demonstrating reactivity with OSM, bovine submaxillary mucin, and synthetic glycoconjugates sTn-human serum albumin (HSA) and Tn-HSA in enzyme-linked immunosorbent assay and immune stains. Median IgM pre-postvaccination reciprocal titers were 20/80 for Tn-HSA and 10/320 for sTn-HSA. Low level IgG antibody titers against sTn-HSA were detected after vaccination in 7 patients. Toxicity was limited to inflammatory skin reactions at the site of vaccination resulting from the adjuvants. No inflammatory infiltrates were seen in the skin when the modified OSM vaccine was administered in the absence of an immunological adjuvant. These results demonstrate that sTn and Tn can be recognized by the human immune system and that vaccines containing these structures can be administered safely with immunological adjuvants. Attempts to augment the immunogenicity of these carbohydrate antigens by covalent attachment to immunogenic carrier proteins and the use of more potent immunological adjuvants are now being pursued.
Subject(s)
Adjuvants, Immunologic/pharmacology , Antigens, Neoplasm/immunology , Antigens, Tumor-Associated, Carbohydrate/immunology , Colorectal Neoplasms/immunology , Immunoglobulin G/biosynthesis , Immunoglobulin M/biosynthesis , Mucins/immunology , Submandibular Gland/chemistry , Vaccines/immunology , Animals , Antibody Specificity , Antigens, Neoplasm/administration & dosage , Antigens, Tumor-Associated, Carbohydrate/administration & dosage , Colorectal Neoplasms/blood , Colorectal Neoplasms/therapy , Humans , Hypersensitivity, Delayed/immunology , Immune Sera/analysis , Mucins/administration & dosage , Sheep , Vaccines/administration & dosage , Vaccines/adverse effectsSubject(s)
Adenocarcinoma/diagnostic imaging , Carcinoma, Renal Cell/diagnostic imaging , Colonic Neoplasms/diagnostic imaging , Kidney Neoplasms/diagnostic imaging , Neoplasms, Multiple Primary/diagnostic imaging , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Tomography, X-Ray ComputedABSTRACT
The ion permeability of lipid membranes formed on Millipore and Nuclepore filters has been found to exhibit stepwise reductions in electrical resistance in the presence of Forssman antigen, appropriate antiserum and complement. The results appear to support the "hydrophobic doughnut" or transmembrane channel hypothesis, which envisions several polypeptide chains anchoring from more than one terminal complement component to interact with one another within the lipid bilayer. Channel formation in these artificial membranes is believed to be due to the insertion of complement proteins. Concentrations and temperature studies were carried out to ascertain that the electrical responses were owing to the generation of stable channels by complement across the membrane. The diameter of these channels was estimated to be in the order of 100 A.